Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Thermo Fisher Scientific Inc. (TMO): Is It Getting a Good Deal With Life Technologies Corp. (LIFE)?

Thermo Fisher Scientific Inc. (NYSE:TMO) announced today that it will acquire genomics company Life Technologies Corp. (NASDAQ:LIFE) in a $13.6 billion deal. The agreement calls for Thermo Fisher Scientific Inc. (NYSE:TMO) to pay $76 per diluted share, as well as assume around $2.2 billion in Life Technologies’ debt.

Thermo Fisher Scientific Inc. (NYSE:TMO)

Leading up to the sale
Life Technologies Corp. (NASDAQ:LIFE) attracted the interest of several parties when it first announced plans to look for a buyer in January. At that time, reports indicated that at least four private equity firms were approached.

Considerable speculation also centered around the possibility that Roche (OTCBB:RHHBY) could entertain an offer. Roche had previously pursued an acquisition of Life’s rival Illumina, Inc. (NASDAQ:ILMN). However, the potential deal broke down because Illumina wanted a price higher than what Roche was willing to pay. Roche’s chairman made comments then that strongly hinted the company could go after another target. Life Technologies Corp. (NASDAQ:LIFE) seemed to be a strong possibility.

Ultimately, Roche didn’t end up in the final hunt while others did. Sigma-Aldrich Corporation (NASDAQ:SIAL), a maker of chemicals for labs and other life sciences organizations, was one of two parties looking to buy Life Technologies. The other was a private consortium made up of Blackstone Group, Carlisle GroupKKR & Co. L.P. (NYSE:KKR), and Temesek Holdings.

Reuters reported that the private consortium’s highest bid came in at $67 per share, well below that of Thermo Fisher Scientific Inc. (NYSE:TMO). No details were available on amounts offered by Sigma-Aldrich.

In the end, Life Systems’ board of directors went with the higher bid from Thermo Fisher Scientific Inc. (NYSE:TMO). The price represents a 12% premium over the stock’s closing price last week.

Good deal?
There’s really no question about whether this is a good deal for Life Technologies. It definitely is.

Life’s stock traded at less than $55 per share the day before the company announced its plans to find a buyer. And those levels were the highest in well over a year. With the acquisition, shareholders benefit from a 38% increase compared to mid-January.